Literature DB >> 12768521

[Attention-deficit/hyperactivity disorder and substance abuse].

Eugen Davids1, Markus Gastpar.   

Abstract

Recent investigations of possible associations between attention deficit hyperactivity disorder (ADHD) and substance-use disorders are reviewed. ADHD seems to represent a possible risk factor for developing a substance abuse, up to 50% of patients with on continuing ADHD symptoms from childhood were found to develop a substance-use disorder. Based on possible pathophysiological similarities, especially cocaine and nicotine dependence are of focused interest in adolescents and adults with ADHD. The presence of ADHD may influence adolescent and adult substance-use disorders in different ways: earlier age of onset, higher frequency, longer duration of substance abuse and transition from alcohol-abuse to other substance-use disorders. Possible pharmacological and non-pharmacological therapeutic strategies in patients with ADHD and substance abuse are discussed.

Entities:  

Mesh:

Year:  2003        PMID: 12768521     DOI: 10.1055/s-2003-39496

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  3 in total

1.  [Military service with adult attention deficit hyperactivity disorder: adaptability of affected soldiers on active service in the German Armed Forces].

Authors:  P Zimmermann; M Jenuwein; K H Biesold; A Heinz; A Ströhle
Journal:  Nervenarzt       Date:  2011-03       Impact factor: 1.214

2.  Alcohol abuse in Russian delinquent adolescents. Associations with comorbid psychopathology, personality and parenting.

Authors:  Roman A Koposov; Vladislav V Ruchkin; Martin Eisemann; Pavel I Sidorov
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-08       Impact factor: 4.785

3.  Homovanillic acid (HVA) plasma levels inversely correlate with attention deficit-hyperactivity and childhood neglect measures in addicted patients.

Authors:  G Gerra; C Leonardi; E Cortese; A Zaimovic; G Dell'agnello; M Manfredini; L Somaini; F Petracca; V Caretti; M A Saracino; M A Raggi; C Donnini
Journal:  J Neural Transm (Vienna)       Date:  2007-08-10       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.